Trial Profile
Effects of Interleukin-1 Inhibition on C-Reactive Protein Levels, Endothelial Progenitor Cell Mobilization and Endothelial Function in Patients With Coronary Artery Disease.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Rilonacept (Primary)
- Indications Atherosclerosis; Coronary arteriosclerosis
- Focus Therapeutic Use
- 20 Apr 2010 Actual number of patients added to 60 as reported by ClinicalTrials.gov.
- 20 Apr 2010 Actual end date added to 1 Apr 2008 as reported by ClinicalTrials.gov.
- 04 Nov 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.